Page 6 - ஐரோப்பிய சமூகம் க்கு மருத்துவ புற்றுநோயியல் காங்கிரஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஐரோப்பிய சமூகம் க்கு மருத்துவ புற்றுநோயியல் காங்கிரஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஐரோப்பிய சமூகம் க்கு மருத்துவ புற்றுநோயியல் காங்கிரஸ் Today - Breaking & Trending Today

Amgen Reports Second Quarter 2021 Financial Results

Amgen Reports Second Quarter 2021 Financial Results
Amgen today announced financial results for the second quarter of 2021. Key results include: Total revenues increased 5% to $6.5 billion in comparison to the second quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® Repatha ® and our biosimilar …
– Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2021. Key results include:
Total revenues increased 5% to $6.5 billion in comparison to the second quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. ....

Puerto Rico , United States , North Carolina , Neulasta Onpro , Trish Rowland , Roberta Bradway , Eli Lilly , Provention Bio , European Society For Medical Oncology Congress , Xencor Inc , Research Development , Therapeutics Inc , National Comprehensive Cancer Network , Regeneron Pharmaceuticals Inc , Company Lilly , European Commission , Drug Administration , Beigene Ltd , Alexion Pharmaceuticals Inc , Exchange Commission , Japanese Ministry Of Health , Amgen Inc , Us Tax Court , Five Prime Therapeutics , Average Selling Price , Sales Detail ,

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Home / Top News / Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
– Supplemental New Drug Application Planned for Submission in Q1 2021 –
CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO ....

United Kingdom , United States , Comunidad Autonoma De Cataluna , Jessica Rennekamp , Holly Manning , Exchange Commission , European Society For Medical Oncology Congress , Corporate Communications , Agios Pharmaceuticals Inc , Supplemental New Drug Application Planned , Agios Pharmaceuticals , American Society , Updated Safety , European Society , Medical Oncology Congress , Lancet Oncology , Interval Prolongation , Prolonging Drugs , Prescribing Information , Private Securities Litigation Reform Act , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , காமுனிடட தன்னாட்சி டி கடலுள் , ஜெசிகா றெண்னேகம்பி , ஹோலி மானிங் , பரிமாற்றம் தரகு ,

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in .
Agios Pharmaceuticals, Inc.January 17, 2021 GMT
CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib tablets) in patients with previously treated isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma. Data from the study were featured in an oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), which is being held virtually January 15-17, 2021. ....

United Kingdom , United States , Comunidad Autonoma De Cataluna , Jessica Rennekamp , Chris Bowden , Andrew Zhu , Holly Manning , Exchange Commission , European Society For Medical Oncology Congress , Jiahui International Cancer Center , Corporate Communications , Agios Pharmaceuticals Inc , Harvard Medical School , American Society , Massachusetts General Hospital , Harvard Medical , Updated Safety , European Society , Medical Oncology Congress , Lancet Oncology , Interval Prolongation , Private Securities Litigation Reform Act , Investor Relations , Products And Services , Government Regulations , Drug Approvals ,